Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004731 · ClinicalTrials.gov registry record · Phase 1
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01004731 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 7 participants.
The verdict
NCT01004731, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.
Interventions
- DRUG Cetuximab in combination with Carboplatin/Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2001-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004731
The ClinicalTrials.gov registry entry for NCT01004731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab in combination with Carboplatin/Gemcitabine is the first listed.
NCT01004731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004731 about?
NCT01004731 is a clinical study titled "Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer". The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.
What is the current status of trial NCT01004731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2001-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT01004731?
The interventions under investigation include: Cetuximab in combination with Carboplatin/Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01004731?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.